Unique position: With its next-level ability to produce DNA constructs, Stony Brook startup LineaRX is looking to speed up production of critical, anti-cancer chimeric antigen receptor modified T cell (or CAR T) therapies.

By GREGORY ZELLER //OCTOBER 16, 2018

Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical development of a non-viral, plasmid-free chimeric antigen receptor modified T-cell manufacturing platform.

In English: A novel platform designed to develop and manufacture new pharmaceutical treatments, including treatments for different forms of cancer.